|
?:abstract
|
-
Background: COVID-19 infection poses a serious risk to patients and - due to its contagious nature - to those healthcare workers (HCWs) treating them If the mouth and nose of HCWs are irrigated with antimicrobial solutions, this may help reduce the risk of active infection being passed from infected patients to HCWs through droplet transmission or direct contact However, the use of such antimicrobial solutions may be associated with harms related to the toxicity of the solutions themselves, or alterations in the natural microbial flora of the mouth or nose Understanding these possible side effects is particularly important when the HCWs are otherwise fit and well Objectives: To assess the benefits and harms of antimicrobial mouthwashes and nasal sprays used by healthcare workers (HCWs) to protect themselves when treating patients with suspected or confirmed COVID-19 infection Search methods: Information Specialists from Cochrane ENT and Cochrane Oral Health searched the Central Register of Controlled Trials (CENTRAL 2020, Issue 6);Ovid MEDLINE;Ovid Embase and additional sources for published and unpublished trials The date of the search was 1 June 2020 Selection criteria: This is a question that urgently requires evidence, however at the present time we did not anticipate finding many completed randomised controlled trials (RCTs) We therefore planned to include the following types of studies: RCTs;quasi-RCTs;non-randomised controlled trials;prospective cohort studies;retrospective cohort studies;cross-sectional studies;controlled before-and-after studies We set no minimum duration for the studies We sought studies comparing any antimicrobial mouthwash and/or nasal spray (alone or in combination) at any concentration, delivered to HCWs, with or without the same intervention being given to the patients with COVID-19 Data collection and analysis: We used standard Cochrane methodological procedures Our primary outcomes were: (1) incidence of symptomatic or test-positive COVID-19 infection in HCWs;(2) significant adverse event: anosmia (or disturbance in sense of smell) Our secondary outcomes were: (3) viral content of aerosol, when present (if intervention administered to patients);(4) other adverse events: changes in microbiome in oral cavity, nasal cavity, oro- or nasopharynx;(5) other adverse events: allergy, irritation/burning of nasal, oral or oropharyngeal mucosa (e g erosions, ulcers, bleeding), long-term staining of mucous membranes or teeth, accidental ingestion We planned to use GRADE to assess the certainty of the evidence for each outcome
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}